Sign in Subscribe
Cancer research

GLP-1 Receptor Agonists Show Promise in Reducing Obesity-Related Cancer Risk

Strategic Insights

— 2 min read

Researchers have conducted a study of 170,000 patient records to examine the potential link between GLP-1 receptor agonists, such as Wegovy and Ozempic, and a lower risk of obesity-related cancers. The study found that individuals with diabetes who took these medications had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took a different class of diabetes drug. This suggests that GLP-1 receptor agonists may be a valuable tool in preventing or reducing the risk of certain cancers.

Key Takeaways:

  • The study analyzed data from 43 U.S. health systems, comparing two groups: individuals with diabetes who took GLP-1 receptor agonists and those who took a different class of diabetes drug.
  • After four years, those who took GLP-1 receptor agonists had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug.
  • The effect was evident in women, but not statistically significant in men, with 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.
  • The study suggests that GLP-1 receptor agonists may be a valuable tool in preventing or reducing the risk of certain cancers.
  • The findings were released by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago.
  • The study was funded by the National Institutes of Health and led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine.
  • Dr. Ernest Hawk of MD Anderson Cancer Center, who was not involved in the study, noted that "this is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this."

Statistics:

  • 7% lower risk of developing an obesity-related cancer in individuals with diabetes who took GLP-1 receptor agonists compared to those who took a different class of diabetes drug.
  • 8% lower risk of death from any cause in individuals with diabetes who took GLP-1 receptor agonists compared to those who took a different class of diabetes drug.
  • 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.
  • 170,000 patient records were analyzed in the study.

Sources:

  • "This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this," said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study. (The Associated Press)
  • The study was funded by the National Institutes of Health. (The Associated Press)
  • The study was led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine. (The Associated Press)
  • The findings were released by the American Society of Clinical Oncology. (The Associated Press)
  • The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. (The Associated Press)

Read more